Status:
TERMINATED
A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborating Sponsors:
Bristol-Myers Squibb
Ligand Pharmaceuticals
Conditions:
Carcinoma, Non-small-cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The primary aim is to evaluate the safety (Phase I components) of administering bexarotene (Targretin®, LGD1069) oral capsules in combination with two Taxol® and carboplatin (Paraplatin®) schedules to...
Detailed Description
The phase I portion of the study will evaluate the safety of administering bexarotene oral capsules daily at two dose levels (300 mg/m2 and 400 mg/m2) in combination with carboplatin and Taxol®. At le...
Eligibility Criteria
Inclusion
- unresectable stage IIIB or IV NSCLC
- adequate bone marrow, hepatic, thyroid and renal function
Exclusion
- peripheral neuropathy \>= grade 2
- gastrointestinal abnormalities
- known hypersensitivity to retinoids
Key Trial Info
Start Date :
August 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00153842
Start Date
August 1 2001
End Date
March 1 2009
Last Update
March 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States, 03756